Treatment of Atrial Fibrillation: Dronedarone -- Differences Between Amiodaron and Other Antiarrhyth
March 14, Sunday 4:30 PM to 6:00 PM
An ATHENA trial showed that after a 30-month follow up of more than 4,000 atrial fibrillation (AF) and atrial flutter patients, cardiovascular hospitalizations and death occurred 24 percent less in patients administered dronedarone than in those administered a placebo. A post-hoc analysis of the ATHENA trial also showed that those on the drug had a reduction in stroke.

While amiodarone has been on the U.S. market since the mid-1980s, dronedarone is a new-comer. How do physicians gauge the difference between drugs that have been around for decades with newer-generation therapies? In this session. Dr. Peter Smith from Marshfield, Wis., will present anti-arrhythmic case presentations and a panel of distinguished physicians in the EP field will discuss the ramifications.

Location: Room B402

Speaker Information:
Peter N. Smith, MD, Marshfield, Wis.
Melanie T. Gura, MD, Hudson, Ohio
Joseph S. Alpert, MD, Tucson, Ariz.
Sangeeta B. Shah, MD, Harvey, La.

Around the web

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Philips introduced a new CT system at ECR aimed at the rapidly growing cardiac CT market, incorporating numerous AI features to optimize workflow and image quality.

Trimed Popup
Trimed Popup